Now showing items 1-5 of 5
The e-psychonaut drugs’ psychopharmacology
The focus here was on the pharmacological and clinical pharmacological issues pertaining to the vast range of drugs (e.g. synthetic cannabimimetics, synthetic opioids, novel stimulants, novel psychedelics, PCP/ketamine-like ...
The benzydamine experience: A systematic review of Benzydamine abuse
Background: Both prescription and over-the-counter (OTC) drugs recently emerged among novel psychoactive substances (NPS) being reported as ingested for recreational purposes. Among them, benzydamine (BZY), normally ...
Focus on clozapine withdrawal- and misuse-related cases, as reported to the European Medicines Agency (EMA) pharmacovigilance database
Background: Clozapine is of high clinical relevance for the management of both treatment-resistant schizophrenia and psychotic disturbances with concurrent drug misuse. Although the molecule presents with a range of ...
The bridge between classical and ‘synthetic’/chemical psychoses: towards a clinical, psychopathological and therapeutic perspective
The critical spread and dissemination of novel psychoactive substances (NPS), particularly among the most vulnerable youngsters, may pose a further concern about the psychotic trajectories related to the intake of new ...
New psychoactive substances (NPS), psychedelic experiences, and dissociation: clinical and clinical pharmacological issues
Purpose of the review: A significant increase in the number, type, and availability of new psychoactive substances (NPS) with dissociative and psychedelic potential has occurred worldwide over the last few decades. Psychedelic ...